Vice President, Clinical Development – Hematology, Transplant and Cell Therapy
Location: New York, NY (Hybrid)

Reporting to: Chief Medical Officer

Why This Role. Why Now.

Radiopharmaceuticals are one of the fastest-growing and most strategically active segments in biotech and Actinium Pharmaceuticals Inc. (NYSE: ATNM) is at the forefront.

Actinium is building first-in-class targeted radiotherapies by uniquely integrating deep radiochemistry expertise with cancer biology insight. Our pipeline spans solid tumors and hematologic malignancies and includes multiple platform-level partnering opportunities across alpha-emitter therapeutics, combinations, conditioning agents, and manufacturing IP.

As our hematology and transplant conditioning programs advance into late-stage development and combination strategies expand, we are looking for a Vice President level to reflect enterprise-wide impact.

This is a physician executive role with direct influence on portfolio prioritization, regulatory positioning, lifecycle strategy, and external scientific leadership. If you want to define how targeted radiotherapeutics integrate into AML backbones, transplant conditioning, and cellular therapy paradigms, this role places you at the center of that evolution.

The Opportunity

As Vice President, Clinical Development – Hematology & Conditioning, you will set and drive global clinical strategy across Actinium's malignant hematology and transplant/cell therapy conditioning portfolio.

You will serve as Clinical Program Lead for Actimab-A and executive clinical lead for the NCI CRADA collaboration, driving:

- Registrational strategy in AML and related myeloid malignancies
- Mutation-agnostic backbone positioning and combination development
- Regulatory strategy and health authority engagement (U.S. and global)
- Cross-functional execution from IND through potential BLA submission

• Lifecycle expansion into transplant and cellular therapy settings

This is a highly visible leadership role partnering closely with Regulatory, Clinical Operations, CMC, Translational Medicine, Biostatistics, Commercial Strategy, and Executive Leadership, with regular interaction at the Board level.

Key Responsibilities

Enterprise Clinical Strategy & Portfolio Leadership

• Define and lead clinical development strategy across hematologic malignancies and transplant/cell therapy conditioning programs

• Serve as Clinical Program Lead for Actimab-A, positioning it as a mutation-agnostic radiotherapeutic backbone in AML

• Design and oversee Phase 1–3 trials in AML and related myeloid diseases

• Drive combination strategies with targeted therapies, hypomethylating agents, and cellular therapies

• Shape lifecycle planning, label expansion, and differentiation strategy

• Provide executive-level medical oversight of safety, data interpretation, and benefit-risk assessment

• Contribute to portfolio prioritization and resource allocation decisions

NCI CRADA & External Scientific Leadership

• Serve as executive clinical lead for Actinium's CRADA collaboration with the National Cancer Institute

• Drive joint development planning, protocol strategy, and regulatory alignment

• Maintain strong relationships with transplant centers, leukemia investigators, and cooperative groups

• Represent Actinium at major scientific congresses (e.g., ASH, ASTCT) and advisory boards

• Serve as a senior scientific ambassador to investigators, partners, and KOLs

Regulatory & Cross-Functional Executive Leadership

• Lead clinical components of FDA/EMA briefing documents and global health authority interactions

• Guide regulatory strategy aligned with accelerated approval, breakthrough designation, and expedited pathways

• Oversee contributions to INDs, BLAs, CSRs, integrated summaries, and safety reports

• Chair or co-chair cross-functional development governance forums

• Oversee safety signal detection, risk mitigation strategy, and DSMB/DMC interactions

• Partner with Commercial and Market Access teams on evidence-generation strategy

Operational & Team Leadership

• Provide executive oversight of protocol development and key clinical documents (IBs, ICFs, DMC charters)

• Guide site selection strategy focused on transplant and high-volume leukemia centers

• Review clinical data and support interim analyses and go/no-go decisions

• Contribute to clinical budget strategy and CRO/vendor oversight

• Build, mentor, and scale the hematology clinical team

• Foster a culture of scientific rigor, accountability, and cross-functional collaboration

What You Bring

• MD (or equivalent medical degree)

• 10+ years of progressive industry clinical development experience

• Deep expertise in hematologic malignancies, particularly AML and high-risk MDS

• Training or significant experience in: Hematopoietic stem cell transplantation, cellular therapies (CAR-T, NK, or related platforms)

• Prior biotechnology or pharmaceutical leadership experience

• Experience leading FDA interactions and global regulatory engagements

• Demonstrated leadership of cross-functional, late-stage development programs

• Experience with radiopharmaceuticals, ADCs, immunotherapy, or targeted oncology platforms

• Prior academic appointment or strong transplant/leukemia center network

• Familiarity with NCI-sponsored, cooperative group, or CRADA-based collaborations

• Executive presence and ability to represent the company externally at the highest levels

Why Actinium

• Late-stage targeted radiotherapy platform in hematologic malignancies

• Proprietary AWE (Antibody Warhead Enabling) technology platform

• Direct executive visibility and influence on portfolio and lifecycle strategy

• Opportunity to shape the clinical positioning of next-generation alpha therapeutics

• Agile, science-driven culture

• Competitive compensation including base, bonus, and equity participation